Judges do not have the power to approve a class action settlement without first issuing an opt-out notice to group members, the court-appointed contradictor in two shareholder class actions against online fashion retailer Surfstitch told the NSW Supreme Court Thursday.
Private education provider Ashley Services may be close to settling a shareholder class action, according to a court order sending the parties in the case to a second mediation session before the end of the year.
An appeals court has rejected the funder’s commission and legal fees stemming from a $64 million settlement in litigation over the failure of Banksia Securities, but granted approval to the settlement.
Generic Health has shaved two percent off the $25 million damages awarded pharmaceutical giant Bayer in a patent infringement case over Bayer’s blockbuster oral contraceptive, Yasmin, but the discount is a far cry from the 15 percent it sought on appeal.
As judges grapple with fierce competition among litigation funders and law firms to lead class actions, Lawyerly asked two leading practitioners on opposing sides of the class action divide to give us their take on the issue.
Actor Geoffrey Rush is seeking to suppress an amended defence by Nationwide News, arguing that if they’re made public the amendments could cause him “irreparable harm”.
A Federal Court judge has rejected a revised pleading in a class action against Ford over its allegedly defective PowerShift transmissions.
The presence of a seconded Ashurst lawyer at a Fair Work Commission hearing in an unfair dismissal case against Qantas did not violate an order denying the airline’s request to hire the firm to represent it in the case, the Fair Work Commission has found.
The administrators of collapsed startup Unlockd have withdrawn the company’s case against Google alleging the search engine giant abused its dominance to keep it out of the digital ad market.
Generic drug maker Alphapharm has lost another bid for documents from Sanofi-Aventis in advance of a hearing on Sanofi’s interlocutory application seeking to block the generic drug maker from listing its injector pen on the Pharmaceutical Benefits Scheme.